Neurocrine Biosciences Inc (NBIX)
125.00
+1.71
(+1.39%)
USD |
NASDAQ |
Nov 21, 16:00
125.00
0.00 (0.00%)
Pre-Market: 08:53
Neurocrine Biosciences Total Liabilities (Quarterly): 816.10M for Sept. 30, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 816.10M |
| June 30, 2024 | 795.80M |
| March 31, 2024 | 1.086B |
| December 31, 2023 | 1.019B |
| September 30, 2023 | 846.10M |
| June 30, 2023 | 760.10M |
| March 31, 2023 | 675.30M |
| December 31, 2022 | 660.90M |
| September 30, 2022 | 598.80M |
| June 30, 2022 | 582.30M |
| March 31, 2022 | 753.40M |
| December 31, 2021 | 698.50M |
| September 30, 2021 | 671.30M |
| June 30, 2021 | 677.20M |
| March 31, 2021 | 640.80M |
| December 31, 2020 | 608.50M |
| September 30, 2020 | 698.30M |
| June 30, 2020 | 684.40M |
| March 31, 2020 | 661.60M |
| December 31, 2019 | 669.10M |
| September 30, 2019 | 605.42M |
| June 30, 2019 | 583.16M |
| March 31, 2019 | 548.45M |
| December 31, 2018 | 512.39M |
| September 30, 2018 | 486.23M |
| Date | Value |
|---|---|
| June 30, 2018 | 463.88M |
| March 31, 2018 | 441.87M |
| December 31, 2017 | 445.45M |
| September 30, 2017 | 424.98M |
| June 30, 2017 | 408.85M |
| March 31, 2017 | 42.22M |
| December 31, 2016 | 50.21M |
| September 30, 2016 | 47.51M |
| June 30, 2016 | 48.80M |
| March 31, 2016 | 46.37M |
| December 31, 2015 | 50.33M |
| September 30, 2015 | 45.49M |
| June 30, 2015 | 44.26M |
| March 31, 2015 | 43.05M |
| December 31, 2014 | 34.33M |
| September 30, 2014 | 33.71M |
| June 30, 2014 | 32.69M |
| March 31, 2014 | 32.24M |
| December 31, 2013 | 34.27M |
| September 30, 2013 | 36.68M |
| June 30, 2013 | 38.80M |
| March 31, 2013 | 38.97M |
| December 31, 2012 | 41.61M |
| September 30, 2012 | 49.95M |
| June 30, 2012 | 57.35M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
582.30M
Minimum
Jun 2022
1.086B
Maximum
Mar 2024
730.21M
Average
680.80M
Median
Total Liabilities (Quarterly) Benchmarks
| Repligen Corp | 813.96M |
| West Pharmaceutical Services Inc | 923.00M |
| Bruker Corp | 4.270B |
| The Cooper Companies Inc | 4.183B |
| Integra Lifesciences Holdings Corp | 2.544B |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 3.535B |
| Shareholders Equity (Quarterly) | 2.719B |
| Current Ratio | 4.367 |
| Net Debt Paydown Yield | 0.29% |